Register Now: Does Your Pharmaceutical WMS Grow with You?
News|Articles|May 31, 2024

Pharma Pulse 5/31/24: Gen Z’s Passion for Skincare Falls Short on Sun Protection, A Long, But Promising Road Ahead in Clinical Trials & more

The latest news for pharma industry insiders.

AI in Clinical Trials: A Long, But Promising Road Ahead

Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.

Gen Z’s Passion for Skincare Falls Short on Sun Protection, AAD Study Finds

In a recent American Academy of Dermatology survey, it was revealed that 52% of Gen Z adults ages 18 to 26 are unaware of key sunburn risks, such as increased skin cancer risk and premature aging.

OpenAI Says Russia and China Used Its A.I. in Covert Campaigns

Iran and an Israeli company also exploited the tools in online influence efforts, but none gained much traction, an OpenAI report said.

GoodRx Named One of the 2024 TIME100 Most Influential Companies

GoodRx, the leading destination for prescription savings in the U.S., was named to the fourth-annual TIME100 Most Influential Companies list, which highlights companies making an extraordinary impact around the world. This is the second time GoodRx has received this honor for helping Americans get the medications they need at a price they can afford.

FDA on Threads:

Ever heard of Apetamin?

You may have seen this product being marketed illegally on social media for weight gain and figure augmentation.

Beware that Apetamin is potentially dangerous and has not been reviewed for safety and effectiveness.

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs


Related to this article

CVS Pharmacy Sign at Storefront Entrance | © Mark Roger Bailey - stock.adobe.com 557616813
In this week’s Pharma Pulse, CVS Health plans to separate into two public companies, Bayer weighs what MFN pricing could mean for its launch strategies and an ACTO survey finds most life sciences leaders see no clear industry standard for responsible AI.